Centiva Capital LP Sells 304 Shares of Cencora, Inc. (NYSE:COR)

Centiva Capital LP lowered its position in shares of Cencora, Inc. (NYSE:COR) by 5.0% during the fourth quarter, HoldingsChannel reports. The fund owned 5,795 shares of the company’s stock after selling 304 shares during the quarter. Centiva Capital LP’s holdings in Cencora were worth $1,302,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of COR. Price T Rowe Associates Inc. MD increased its stake in shares of Cencora by 0.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company’s stock valued at $1,990,542,000 after buying an additional 78,066 shares during the period. Bank of America Corp DE increased its position in Cencora by 62.3% in the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock valued at $1,166,944,000 after acquiring an additional 1,994,256 shares during the period. Boston Partners raised its stake in shares of Cencora by 2.6% during the fourth quarter. Boston Partners now owns 5,007,100 shares of the company’s stock valued at $1,128,058,000 after acquiring an additional 125,611 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Cencora by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company’s stock worth $969,471,000 after purchasing an additional 130,213 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Cencora by 20.4% in the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company’s stock worth $728,757,000 after purchasing an additional 550,246 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on COR. JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Wells Fargo & Company raised their price objective on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Finally, UBS Group increased their price target on Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a research report on Tuesday, April 29th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $290.00.

Cencora Price Performance

COR opened at $304.04 on Thursday. The company has a market capitalization of $58.96 billion, a price-to-earnings ratio of 43.25, a PEG ratio of 1.31 and a beta of 0.60. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a 50-day moving average price of $275.33 and a 200-day moving average price of $252.65. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $309.35.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to analysts’ expectations of $75.41 billion. During the same quarter in the previous year, the firm posted $3.80 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at $13,022,850. This trade represents a 8.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock worth $13,580,967 in the last quarter. 10.80% of the stock is owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.